219 related articles for article (PubMed ID: 16696787)
1. Alosetron: ischemic colitis and serious complications of constipation.
Gallo-Torres H; Brinker A; Avigan M
Am J Gastroenterol; 2006 May; 101(5):1080-3. PubMed ID: 16696787
[TBL] [Abstract][Full Text] [Related]
2. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
Chang L; Tong K; Ameen V
Am J Gastroenterol; 2010 Apr; 105(4):866-75. PubMed ID: 20197759
[TBL] [Abstract][Full Text] [Related]
3. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.
Chang L; Chey WD; Harris L; Olden K; Surawicz C; Schoenfeld P
Am J Gastroenterol; 2006 May; 101(5):1069-79. PubMed ID: 16606352
[TBL] [Abstract][Full Text] [Related]
4. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Lewis JH
Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
[TBL] [Abstract][Full Text] [Related]
7. Glaxo Wellcome withdraws irritable bowel syndrome medication.
FDA Consum; 2001; 35(1):3. PubMed ID: 11930921
[No Abstract] [Full Text] [Related]
8. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
Miller DP; Alfredson T; Cook SF; Sands BE; Walker AM
Am J Gastroenterol; 2003 May; 98(5):1117-22. PubMed ID: 12809837
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
[TBL] [Abstract][Full Text] [Related]
10. Possible mechanisms for ischemic colitis during alosetron therapy.
Beck IT
Gastroenterology; 2001 Jul; 121(1):231-2. PubMed ID: 11441889
[No Abstract] [Full Text] [Related]
11. Safety concerns about alosetron.
Camilleri M
Arch Intern Med; 2002 Jan; 162(1):100-1. PubMed ID: 11784232
[No Abstract] [Full Text] [Related]
12. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
[TBL] [Abstract][Full Text] [Related]
13. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment of irritable bowel syndrome--from concept to sales.
Kamm MA
Eur J Surg Suppl; 2002; (587):10-5. PubMed ID: 16144196
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
Wolfe SG; Chey WY; Washington MK; Harding J; Heath AT; McSorley DJ; Dukes GE; Hunt CM
Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555
[TBL] [Abstract][Full Text] [Related]
16. Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
Schiller LR; Johnson DA
Am J Gastroenterol; 2008 Apr; 103(4):815-9. PubMed ID: 18397418
[TBL] [Abstract][Full Text] [Related]
17. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
[No Abstract] [Full Text] [Related]
18. Alosetron and irritable bowel syndrome.
Mayer EA; Bradesi S
Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
[TBL] [Abstract][Full Text] [Related]
19. Lotronex withdrawal.
Lisi DM
Arch Intern Med; 2002 Jan; 162(1):101. PubMed ID: 11784233
[No Abstract] [Full Text] [Related]
20. Review article: the safety profile of tegaserod.
Schoenfeld P
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
